NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said yesterday that it has completed its previously announced underwritten public offering.

The company sold approximately 13.9 million shares of its common stock at a price to the public of $2.90 per share, including about 1.8 million shares pursuant to the exercise in full of the underwriters' option to purchase additional shares.